Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. (21st April 2010)

• Record Type: Journal Article
• Authors: Ruggenenti, Piero; Iliev, Ilian; Filipponi, Marco; Tadini, Stefano; Perna, Annalisa; Ganeva, Maria; Ene-Iordache, Bogdan; Cravedi, Paolo; Trevisan, Roberto; Bossi, Antonio; Remuzzi, Giuseppe
• Other Names: Kowluru Renu A. Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2010(2010)
• Publication Date: 2010-04-21
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2010/106384
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Background . The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods . We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results . Over a median (interquartile range) follow-up period of 35.8 (12.4–60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18–6.42), P = .0193 ). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions . Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy.